Open Access
Issue
E3S Web Conf.
Volume 245, 2021
2021 5th International Conference on Advances in Energy, Environment and Chemical Science (AEECS 2021)
Article Number 03052
Number of page(s) 7
Section Chemical Performance Research and Chemical Industry Technology Research and Development
DOI https://doi.org/10.1051/e3sconf/202124503052
Published online 24 March 2021
  1. Zhu, N., et al., A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med, 2020. 382(8): p. 727-733. [Google Scholar]
  2. Vincent J. Munster Ph.D., M.K., D. V. M., Neeltje van Doremalen, Ph.D., Debby van Riel, Ph.D., and Emmie de Wit, Ph.D., A Novel coronavirus Emerging in China——Key Questions for empact assessment. [Google Scholar]
  3. Can, A. and H. Coskun, The rationale of using mesenchymal stem cells in patients with COVID-19-related acute respiratory distress syndrome: What to expect. Stem Cells Transl Med, 2020. [Google Scholar]
  4. Lan, J., et al., Crystal structure of the 2019-nCoV spike receptor-binding domain bound with the ACE2 receptor. 2020. [Google Scholar]
  5. Wrapp, D., et al., <Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation.pdf>. Science, 2020. 367(6483). [Google Scholar]
  6. Yan, R., et al., <Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2.pdf>. Science, 2020. 367(6485). [Google Scholar]
  7. Hamming, I., et al., The emerging role of ACE2 in physiology and disease. J Pathol, 2007. 212(1): p. 1-11. [Google Scholar]
  8. Tok, T.T. and G. Tatar, Structures and Functions of Coronavirus Proteins: Molecular Modeling of Viral Nucleoprotein SCIRES Literature. 2(1). [Google Scholar]
  9. Wang, K., W. Chen, and Y.-S. Zhou, <SARS-CoV-2 invades host cells via a novel route CD147-spike protein.pdf>. [Google Scholar]
  10. Curtin, K.D., I.A. Meinertzhagen, and R.J. Wyman, Basigin (EMMPRIN/CD147) interacts with integrin to affect cellular architecture. J Cell Sci, 2005. 118(Pt 12): p. 2649-60. [Google Scholar]
  11. Catanzaro, M., et al., Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2. Signal Transduction and Targeted Therapy, 2020. 5(1). [Google Scholar]
  12. Moore, J.B. and C.H. June, <Cytokine release syndrome in severe COVID-19.pdf>. Science, 2020. 368(6490). [Google Scholar]
  13. Gao, Q., et al., <Development of an inactivated vaccine candidate for SARS-CoV-2.pdf>. 2020. 369(6499). [Google Scholar]
  14. Hoffmann, M., et al., SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020. 181(2): p. 271-280 e8. [CrossRef] [PubMed] [Google Scholar]
  15. Xia, S., et al., Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res, 2020. 30(4): p. 343-355. [PubMed] [Google Scholar]
  16. Shi, R., et al., A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature, 2020. 584(7819): p. 120-124. [PubMed] [Google Scholar]
  17. Kosugi, T., et al., CD147 (EMMPRIN/Basigin) in kidney diseases: from an inflammation and immune system viewpoint. Nephrology Dialysis Transplantation, 2015. 30(7): p. 1097-1103. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.